Is bngo a good stock to invest in?
Aug 05, 2021 · Bionano Genomics, Inc. (BNGO) stock was dropping in the pre-market today following the announcement of Q2 2021 financial results. BNGO stock saw a downtrend of 3.24% to drop at $3.24 a share at the time of this writing. The stock was also gloomy in the previous trade and went down by 1.01% at closing. Let’s deep dive to explore more of it.
Is BioNano genomics (bngo) stock breaking down?
Feb 25, 2021 · That leaves investors today open to big losses if BNGO falls back to penny stock levels, where it spent most of 2020. That’s why BNGO stock started to drop on Feb. 16 and why it crashed again on ...
How often do you update the bngo stock projections?
BNGO is not down much for a market drop like this. ... I do believe BNGO latest upgrade announcement 4/7/2022 yesterdy of NxCliniec 6.2 will be a catalyst for taking BNGO stock back over $5 or $10 ...
Why is bngo stock on a wild ride?
Why Bionano Genomics Stock Is Risky, but a Good Bet. Bionano (BNGO) made solid progress with its business last year. It is building a robust ecosystem with a recurring revenue outlook.
Is BNGO a buy or sell?
Bionano Genomics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.
Is BNGO expected to rise?
Bionano Genomics Inc (NASDAQ:BNGO) The 4 analysts offering 12-month price forecasts for Bionano Genomics Inc have a median target of 7.50, with a high estimate of 14.00 and a low estimate of 6.00. The median estimate represents a +278.79% increase from the last price of 1.98.
Is BNGO a good investment?
Based on his analysis, DeGeeter rates BNGO stock as “outperform” with a $14 value. Other analysts are also bullish on the company. Those tracked by the Wall Street Journal have BNGO rated as a consensus “buy” with an average $12 price target.Dec 14, 2021
Is BNGO stock undervalued?
Bionano (BNGO) Stock May Still Be Undervalued by Over 100%, Analyst Says.Aug 25, 2020
Who owns BioNano genomics?
The Vanguard Group, Inc.
Is BNGO a pump and dump?
BNGO stock has suffered at the hands of a Ritalin-using pump and dump scheme making waves in 2021.May 7, 2021
How much will BNGO be worth?
Bionano Genomics net worth as of April 13, 2022 is $0.62B. BioNano Genomics, Inc.
Does ARKG hold BNGO?
Does ARK Invest in BNGO: The Bottom Line. At this time, ARK does not invest in BNGO. With that said, the company does appear to have some promise in its own right. Like all speculative small-cap companies, Bionano Genomics is a risky stock to own.
What is BNGO price target?
Stock Price TargetsHigh$14.00Median$7.50Low$6.00Average$8.75Current Price$1.9800
What type of stock is BNGO?
Common Stock (BNGO)
What does BNGO company do?
The firm engages in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline cytogenetics.
What does BioNano genomics do?
Bionano Genomics, Inc. provides a platform to analyze the long segments of genomic DNA and other biomolecules structural variations. The Company offers proprietary nanochannel chips, automated imaging instrument, integrated primary and secondary software, and application specific reagents.
The Reddit Effect Strikes Again
Bottom Line on BNGO Stock
One of the big news stories of 2021 has been the Reddit effect. Retail investors have been using the platform to drive up the prices of many stocks that were previously struggling and attracting short-sellers.
Is Bionano stock undervalued?
BioNano doesn’t get the degree of analyst coverage that headline-grabbing biotech companies have over the past year. CNN Money is following just four investment analysts that cover BNGO stock.
Is robotic surgery futuristic?
But unlike most other meme names, Bionano has a highly disruptive product, and its shares are tremendously undervalued. BNGO stock is down 20.8% in the past month.
Bionano Grows Revenue From a Small Base
One is a robotic surgery leader, another is a rising star in genome analysis, and the third is a coronavirus vaccine maker with a hefty and diversified pipeline. The idea of robotic surgery may seem futuristic. The company has installed more than 6,000 of its Da Vinci surgical systems worldwide.
Much More Work to Be Done
Bionano announced its third-quarter results on Nov. 4. Revenue shot up 112% to $4.7 million, from $2.2 million a year ago, beating Wall Street’s expectations for the sixth consecutive quarter. While the company delivered triple-digit percentage growth, keep in mind that the baseline revenue number was still very small.
The Bottom Line on BNGO Stock
What a lot of people don’t realize is that science is only half the equation for building a successful medtech business. Adoption of new technology in the medical field can be slow. It often takes a strong sales team to convince doctors to try something new.
Bionano Genomics (BNGO-Q)
The expansion of Bionano’s sales and marketing team with industry veterans is a big step in the right direction. But I must admit that I am getting a little impatient. The company needs to quickly accelerate the adoption of Saphyr to grow its revenue and support current valuations.
Bionano Genomics (BNGO-Q)
This is as speculative as you can get. It shares plunged in half, nobody would care.
Bionano Genomics (BNGO-Q) Rating
He used to recommend this, but it was since run up. Buy this only if you want a spec.
Bionano Genomics (BNGO-Q) Frequently Asked Questions
Stockchase rating for Bionano Genomics is calculated according to the stock experts' signals. A high score means experts mostly recommend to buy the stock while a low score means experts mostly recommend to sell the stock.
